Spire Wealth Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
PCH
RI
PHS
PAMS
Spire Wealth Management's CYTK Position: Q2 2023 in Review
Spire Wealth Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 43 shares — an estimated $1.51K sold.
Spire Wealth Management first reported a position in CYTK in Q4 2022 and held it in 2 quarters. The position peaked at $2K in Q4 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.
- Spire Wealth Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
- Spire Wealth Management sold 43 Cytokinetics shares in Q2 2023, an estimated $1.51K.
- Spire Wealth Management first reported a position in Cytokinetics in Q4 2022 and held it in 2 quarters.
- Spire Wealth Management's Cytokinetics position peaked at $2K in Q4 2022.
- 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.
Based on Spire Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.